1. Home
  2. DOCU vs CINGW Comparison

DOCU vs CINGW Comparison

Compare DOCU & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DOCU
  • CINGW
  • Stock Information
  • Founded
  • DOCU 2003
  • CINGW N/A
  • Country
  • DOCU United States
  • CINGW United States
  • Employees
  • DOCU N/A
  • CINGW 13
  • Industry
  • DOCU EDP Services
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • DOCU Technology
  • CINGW Health Care
  • Exchange
  • DOCU Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • DOCU N/A
  • CINGW N/A
  • IPO Year
  • DOCU 2018
  • CINGW 2021
  • Fundamental
  • Price
  • DOCU $83.96
  • CINGW $0.04
  • Analyst Decision
  • DOCU Hold
  • CINGW
  • Analyst Count
  • DOCU 16
  • CINGW 0
  • Target Price
  • DOCU $89.38
  • CINGW N/A
  • AVG Volume (30 Days)
  • DOCU 2.0M
  • CINGW N/A
  • Earning Date
  • DOCU 03-06-2025
  • CINGW N/A
  • Dividend Yield
  • DOCU N/A
  • CINGW N/A
  • EPS Growth
  • DOCU 1852.18
  • CINGW N/A
  • EPS
  • DOCU 4.82
  • CINGW N/A
  • Revenue
  • DOCU $2,912,873,000.00
  • CINGW N/A
  • Revenue This Year
  • DOCU $9.38
  • CINGW N/A
  • Revenue Next Year
  • DOCU $6.42
  • CINGW N/A
  • P/E Ratio
  • DOCU $17.43
  • CINGW N/A
  • Revenue Growth
  • DOCU 7.52
  • CINGW N/A
  • 52 Week Low
  • DOCU $48.70
  • CINGW N/A
  • 52 Week High
  • DOCU $107.86
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • DOCU 31.31
  • CINGW N/A
  • Support Level
  • DOCU $85.32
  • CINGW N/A
  • Resistance Level
  • DOCU $89.45
  • CINGW N/A
  • Average True Range (ATR)
  • DOCU 3.18
  • CINGW 0.00
  • MACD
  • DOCU -1.00
  • CINGW 0.00
  • Stochastic Oscillator
  • DOCU 3.52
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: